The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About AutoCyte

Developer of cytology, pathology, and immunology products. These products relate to improved preparatory techniques, new diagnostic systems, objective detection, and measurement systems employing image analysis. AutoCyte has recently been granted 510(k) clearance from the FDA to begin marketing a workstation for antinuclear antibodies using an indirect immunofluorescent assay test kit. Recent applications include screening systems for cervical cancer. The company is currently selling products in foreign countries and is pursuing regulatory approval in the United States.

AutoCyte Headquarter Location

112 Orange Drive

North Carolina, 27244,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was AutoCyte founded?

    AutoCyte was founded in 1996.

  • What is AutoCyte's latest funding round?

    AutoCyte's latest funding round is IPO.

  • How much did AutoCyte raise?

    AutoCyte raised a total of $9.68M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.